Research analysts at StockNews.com started coverage on shares of InVivo Therapeutics (NASDAQ:NVIV – Get Rating) in a report released on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock.
InVivo Therapeutics Stock Down 1.7 %
NVIV opened at $0.96 on Friday. The stock’s fifty day moving average is $2.06 and its two-hundred day moving average is $2.78. InVivo Therapeutics has a 52 week low of $0.91 and a 52 week high of $13.77. The company has a market capitalization of $2.75 million, a P/E ratio of -0.12 and a beta of 0.85.
Hedge Funds Weigh In On InVivo Therapeutics
Large investors have recently modified their holdings of the business. Armistice Capital LLC acquired a new position in shares of InVivo Therapeutics in the fourth quarter worth $522,000. Two Sigma Advisers LP acquired a new position in InVivo Therapeutics in the 3rd quarter valued at $45,000. Two Sigma Investments LP purchased a new position in InVivo Therapeutics during the third quarter worth about $49,000. Vanguard Group Inc. acquired a new stake in shares of InVivo Therapeutics in the 3rd quarter valued at approximately $73,000. Finally, Citadel Advisors LLC lifted its holdings in InVivo Therapeutics by 182.9% in the third quarter. Citadel Advisors LLC now owns 42,794 shares of the biotechnology company’s stock valued at $184,000 after acquiring an additional 27,667 shares during the period. Institutional investors and hedge funds own 8.60% of the company’s stock.
InVivo Therapeutics Company Profile
Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. Its clinical development program is the Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord.
- Get a free copy of the StockNews.com research report on InVivo Therapeutics (NVIV)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for InVivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.